Oncotarget awards grants to four biomedical researchers at Frontiers in Cancer Science
ORCHARD PARK, New York – (Dec. 6, 2017) – Oncotarget, the world's largest oncology peer-reviewed research publication, awarded travel grants enabling four biomedical researchers to attend November's Frontiers in Cancer Science 2017 (FCS 2017) conference in Singapore. The travel sponsorship encourages the discussion of cancer discoveries in support of Oncotarget's commitment to maximizing the circulation of scientific research.
"We're dedicated to the wide dissemination of scientific advances to improve understanding and spur future discoveries," said Mikhail Blagosklonny, Oncotarget's editor-in-chief. "The Frontiers in Cancer Science meeting brings together top cancer experts from around the globe and as travel sponsor, Oncotarget is proud to have provided the opportunity for new and groundbreaking research from four international institutions to be shared at the meeting."
The sponsored researchers presented studies ranging from assessing the impact of drug treatments on kidney cancer to characterizing the chemoresistance of asbestos-related tumors. The researchers and their presentations are as follows:
- Mohd Anas Shamsi, Department of Biochemistry F/O Life Sciences, Aligarh Muslim University, India – Global Transition of Human Serum Albumin to Prefibrillar Aggregates Induced by Temsirolimus: Insight into Implications of Anti-Renal Cancer Drug
- Rajni Kumari, National Institute of Immunology, India – Hit Where It Hurts: Epigenetic Alteration of Proliferative and Metastatic Genes by Caspase-10
- Ruhi Sandeep Deshmukh, Molecular Oncology Laboratory, National Institute of Immunology, India – Cyclin F is a Novel Regulator of Glioma Epigenetics
- Vladan Milosevic, Department of Oncology, University of Torino, Italy – Wnt/c-myc/ABCB5 Determines Chemoresistance in Cancer Stem Cells of Malignant Pleural Mesothelioma
The FCS 2017 conference, which was held November 6 – 8, was hosted by seven major research institutes: Cancer Science Institute of Singapore, Duke-NUS Medical School, Genome Institute of Singapore, Institute of Molecular and Cell Biology and Lee Kong Chian School of Medicine.
For more biomedical research in oncology and related areas such as immunology and microbiology, the latest issue of Oncotarget is available at http://www.impactjournals.com/oncotarget.
Oncotarget is a twice-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology such as Aging, Immunology and Microbiology, Autophagy, Pathology and Chromosomes and more. Oncotarget is published by Rapamycin Press, the publishing division of Impact Journals LLC.
Ryan James Jessup